Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MLTX vs INVA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INVA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

INVA Overall Winner 6-Pillar Tally: MLTX 1 – 5 INVA Matrix Metrics: MLTX 2 – 8 INVA

As of Nov 16, 2026, Innoviva, Inc. (INVA) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MLTX carries a Unified Composite Score of 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin), whereas INVA carries 48.9/100 (HOLD) at $18.59 (8.8x Forward P/E, 39.5% operating margin).

  • Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile INVA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MLTX vs INVA
MLTX NASDAQ
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.61β · 90% Vol
Unified Composite Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -11.8%) with fading momentum, RSI 50
RSI-14: 49.5 · SMA20: $11.93 · SMA50: $11.82
INVA NASDAQ Head-to-Head Winner
Innoviva, Inc. Common Stock
Pharmaceutical Preparations
$18.59
-2.34% 1D
Market Cap $1.3B
TTM Revenue $438M
Forward P/E 8.8x
Beta / 30D Vol 0.32β · 37% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 39.0 Fund 59.0 Flow 66.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.6%), weak momentum, RSI 29
RSI-14: 29.4 · SMA20: $20.23 · SMA50: $20.64

6-Pillar Scorecard Institutional Category Breakdown (MLTX 1 – 5 INVA)

Columns: Metric · MLTX · INVA
1. Valuation Multiples INVA
Forward P/E N/M 8.8x
Trailing P/E N/M 8.1x
PEG Ratio N/M 2.82x
EV / Revenue N/M 2.4x
2. Growth & Scale INVA
Revenue Growth (YoY) +0.0% -1.6%
Earnings Growth (YoY) +0.0% +590.4%
TTM Revenue (USD) N/A $438M
Market Cap $1.1B $1.3B
3. Profitability & Quality INVA
Gross Margin N/A 77.0%
Operating Margin 0.0% 39.5%
Net Profit Margin 0.0% 44.1%
Return on Equity (ROE) -81.5% 18.0%
4. Balance Sheet & Cash Flow INVA
Cash Generation (TTM) -$244M $183M
Cash Flow Margin N/A 41.6%
Net Cash / Leverage $278M Net Cash $312M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MLTX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 111.8% (7th %ile) 23.8% (4th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat INVA
OpEx & R&D Intensity N/A 37.5% of Rev ($164M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MLTX (2) vs INVA (8)
Institutional Metric MLTX INVA Criterion Row Edge
Market Capitalization
Scale
$1.1B $1.3B Larger Scale INVA
Trailing P/E Ratio
Valuation
N/M 8.1x Lower Multiple INVA
Forward P/E Ratio
Valuation
N/M 8.8x Lower Multiple INVA
Revenue Growth (YoY)
Growth
+0.0% -1.6% Higher Growth MLTX
Operating Margin (TTM)
Profitability
0.0% 39.5% Higher Margin INVA
Net Profit Margin
Profitability
0.0% 44.1% Higher Margin INVA
Return on Equity (ROE)
Capital Efficiency
-81.5% 18.0% Higher ROE INVA
52-Week Range Position
Momentum
17% ($9–$23) 2% ($18–$25) Stronger Trend MLTX
Beta / 30D Volatility
Risk Regime
1.61β · 90% Vol 0.32β · 37% Vol Lower Realized Risk INVA
Unified Institutional Score
Composite Signal
38.3 / 100 (SELL) 48.9 / 100 (HOLD) Higher Composite INVA
Trailing 12M Revenue (USD)
Operating Scale
N/A $438M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 77.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 2.82x PEG · 2.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$244M ($278M Net Cash) $183M ($312M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MLTX +34.64 pp
MLTX: +24.08% · INVA: -10.56%
3M Horizon INVA +14.94 pp
MLTX: -27.48% · INVA: -12.54%
6M Horizon INVA +13.17 pp
MLTX: -27.92% · INVA: -14.75%
1Y Horizon MLTX +10.63 pp
MLTX: -5.65% · INVA: -16.28%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLTX vs INVA. Trailing 12-month operating profitability (MLTX 0.0% vs INVA 39.5%) and valuation multiples (MLTX N/M vs INVA 8.8x Forward P/E) are benchmarked directly in Pillar 4 below.

MLTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-81.5% · N/M
INVA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$438M
Gross Margin77.0%
Op. Margin39.5%
ROE / Fwd P/E18.0% · 8.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MLTX BREAKDOWN
103d in phase · OBV ACCUMULATION
Current IV 111.8%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact MLTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INVA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 23.8%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact INVA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MLTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
INVA Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and 39.5% operating margin.
OpEx & R&D Reinvestment 37.5% of Rev ($164M)
90D Engineering Disclosures 0 Published

Investor FAQ MLTX vs INVA Key Questions & Quantitative Answers

As of Nov 16, 2026, Innoviva, Inc. (INVA) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MLTX carries a Unified Composite Score of 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin), whereas INVA carries 48.9/100 (HOLD) at $18.59 (8.8x Forward P/E, 39.5% operating margin). Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile INVA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

INVA leads the Growth & Scale pillar: MLTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with INVA at -1.6% YoY revenue growth and +590.4% YoY earnings growth on $438M TTM revenue (77.0% gross margin, 39.5% operating margin). On trailing 12-month operating scale, MLTX generates N/A in USD-normalized revenue versus $438M for INVA. In operating R&D and SG&A reinvestment, MLTX deploys N/A (0 90-day corporate R&D disclosures) versus 37.5% of Rev ($164M) (0 disclosures) for INVA.

INVA screens cheaper on headline valuation multiples. MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas INVA trades at 8.8x Forward P/E, 8.1x Trailing P/E, 2.82x PEG, and 2.4x EV/Revenue (41.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLTX (-81.5% ROE) versus INVA (18.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk). By comparison, INVA carries 23.8% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 37% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.